Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;4(2):111-20.
doi: 10.1177/1759720X11425092.

Diagnosis and treatment of inflammatory myopathy: issues and management

Diagnosis and treatment of inflammatory myopathy: issues and management

Christine Castro et al. Ther Adv Musculoskelet Dis. 2012 Apr.

Abstract

The idiopathic inflammatory myopathies include polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM). The specific etiologies of these muscle diseases are not well known and are thought to involve components of the humoral and cellular immune system as well as other nonimmune factors. Diagnosing these myopathies involves a laboratory evaluation, imaging studies, multidisciplinary consultations, histologic examination and potentially genetic studies. Despite all that we currently know about inflammatory muscle disease with these studies, we find that our current concept of muscle disease is changing. In the cases of immune-mediated necrotizing myopathy and inclusion body myositis, the concept of inflammation needs to be rethought. Moreover, the classification schemes for these idiopathic myopathies may need updating to include current research findings that relate to pathogenesis. With ongoing discoveries, classification and appropriate treatment is becoming increasingly challenging. This paper discusses the inflammatory myopathies, the challenges to diagnosis, classification controversies and potential treatment options.

Keywords: inflammatory; muscle biopsy; myopathy; treatment; vacuoles.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

References

    1. Aggarwal R.H., Reed A.M., Ascherman D.P., Barohn F.J., Feldman B.M., Miller F.W., et al. (2010) Predictors of clinical response in rituximab-treated refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) – the RIM study. Arthritis Rheum Late Breaking Abstracts: L6 - PMC - PubMed
    1. Aldao A., Mennin D.S., Linardatos E., Fresco D.M. (2010) Differential patterns of physical symptoms and subjective processes in generalized anxiety disorder and unipolar depression. J Anxiety Disord 24: 250–259 - PubMed
    1. Assumpcao A., Sauer J.F., Mango P.C., Pascual Marques A. (2010) Physical function interfering with pain and symptoms in fibromyalgia patients. Clin Exp Rheumatol 28(6 Suppl. 63): S57–S63 - PubMed
    1. Benveniste O., Drouot L., Jouen F., Charuel J.L., Bloch-Queyrat C., Behin A., et al. (2011) Correlation of anti-signal recognition particle auto-antibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 63: 1961–1971 - PubMed
    1. Bohan A., Peter J.B. (1975a) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344–347 - PubMed

LinkOut - more resources